Form 4: CME Group Executive Sells Shares Under 10b5-1 Plan

CME Group's Senior MD and General Counsel, Jonathan L. Marcus, sold 3,291 shares of Class A Common Stock for $333.37 per share under a pre-arranged 10b5-1 plan.

Summary

• Jonathan L. Marcus, Senior MD and General Counsel of CME Group Inc., reported a sale of company stock.
• The transaction involved 3,291 shares of Class A Common Stock.
• The shares were sold at a price of $333.37 per share.
• The sale was executed on March 17, 2026.
• This transaction was conducted under a Rule 10b5-1 trading plan, which was adopted on February 18, 2025.
• Following this sale, Marcus beneficially owns 7,192 shares of CME Group Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-scheduled under a 10b5-1 plan, which typically indicates personal financial planning rather than a change in sentiment about the company's prospects.

Positives

• The sale was pre-arranged under a Rule 10b5-1 plan, indicating it was not based on new, non-public information and is a routine personal financial management event.

Negatives

• An insider sale reduces the executive's direct ownership stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales under 10b5-1 plans are common for executives to manage personal finances and diversify holdings without implying a negative outlook on the company's future performance. This is a routine disclosure for CME Group Inc.

Comparison to Industry Standards

• Insider sales, particularly those executed under Rule 10b5-1 plans, are a common practice among executives in publicly traded companies across all sectors, including financial services like CME Group. These plans allow executives to sell shares at predetermined times or prices, mitigating concerns about trading on inside information. For example, executives at other major financial exchanges or institutions often utilize similar plans for personal financial planning.

Stakeholder Impact

• Shareholders: A slight reduction in insider ownership, but mitigated by the 10b5-1 plan, suggesting no immediate negative implications for company performance or strategy.

Key Dates

Recommendation

The reported insider sale by Jonathan L. Marcus is a routine transaction executed under a pre-arranged Rule 10b5-1 plan. Such sales are generally for personal financial management and do not typically signal a change in the company's fundamental outlook or warrant an immediate adjustment to an investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring broader company performance and market conditions.

Keywords

CME Group, insider transaction, Form 4, stock sale, Jonathan Marcus, 10b5-1 plan, executive compensation